*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior myocardial infarction, history of heart failure, and prior aspirin use. For comparative effectiveness recommendations (Class I and IIa; Level of Evidence A and B only), studies that support the use of comparator verbs should involve direct comparisons of the treatments or strategies being evaluated. guideline is generally concerned with adults, with issues of hemorrhagic stroke in children and neonates covered in a separate American Heart Association scientific statement on Management of Stroke in Infants and Children. 5 This document serves to update the last ICH guidelines published in 2010,2 and the reader is referred to these guide- lines for additional relevant references not contained here. The development of this update was purposely delayed for 1 year from the intended 3-year review cycle so that results of 2 pivotal phase 3 ICH clinical trials could be incorporated. Differences from recommendations in the 2010 guideline are specified in the current work. The writing group met by phone to determine subcategories to evaluate. These included 15 sections that cov- ered the following: emergency diagnosis and assessment of ICH and its causes; hemostasis and coagulopathy; blood pres- sure (BP) management; inpatient management, including gen- eral monitoring and nursing care, glucose/temperature/seizure management, and other medical complications; procedures, including management of intracranial pressure (ICP), intra- ventricular hemorrhage, and the role of surgical clot removal; outcome prediction; prevention of recurrent ICH; rehabilita- tion; and future considerations. Each subcategory was led by a primary author, with 1 or 2 additional authors making contri- butions. Full PubMed searches were conducted of all English language articles regarding relevant human disease treatment from 2009 through August 2013. 